Mediated - latest news (June 5, 2023)

Thousands of migrants detained at Libyan border in ongoing crackdown, activists report


Libyan activists said authorities in eastern Libya collected thousands of migrants and assembled them in an area on the ...

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities


Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment ...

Iran to reopen embassy in Saudi Arabia, state media says, as enmity softens


After a seven-year closure, Iran announced Monday that it would reopen its embassy in Saudi Arabia this week — a major step in moves to revive relations and soften a rivalry with major consequences ...

When celebrity culture is exposed as the sham it is, we should applaud


In particular, I’m talking about the gullibility of the public when it comes to the industry known as celebrity culture, our ...

Researchers identify novel mechanism of hepatic gluconeogenesis via PHD3-mediated hydroxylation of CRTC2


A team led by Prof. Li Yu from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences (CAS) ...

Sudan: Scores killed as RSF attacks North Darfur's Kutum


Since then, seven barely observed ceasefires mediated by the United States and Saudi Arabia have come and gone. Last week, following the complete breakdown of peace talks, the US imposed sanctions on ...

Why Are Evaxion Biotech Shares Trading Higher Today


Evaxion Biotech A/S (NASDAQ: EVAX) presented clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic ...

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023


CatalYm is pioneering a novel immuno-oncology therapy that safely overcomes GDF-15-mediated immunosuppression in the tumor microenvironment. Our lead product, visugromab, a first-in-class GDF-15 ...

Brensocatib by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval


Brensocatibis under clinical development by AstraZeneca and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023


UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023 Data to be presented on bimekizumab, CIMZIA® (certolizumab pegol), and dapirolizumab ...